CG Oncology, Inc.CGONEarnings & Financial Report
Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)
CG Oncology, Inc. is a clinical-stage biotechnology company focused on developing innovative targeted immunotherapies for urological cancers including non-muscle invasive bladder cancer. It primarily operates in the U.S. market, advancing pipeline candidates to address unmet medical needs for patients with limited treatment options.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| The Vanguard Group | 7.57% | 5.1M | flat | 2024-11-12 |
| Decheng Capital Global Life Sciences Fund IV, L.P. | 7.40% | 5.0M | ▲ +0.50pp | 2024-04-09 |
| BlackRock, Inc. | 5.30% | 3.6M | flat | 2024-11-08 |
| Kissei Pharmaceutical Co., Ltd. | 5.30% | 3.5M | — | 2024-03-14 |
| Longitude Capital Partners IV, LLC | 4.80% | 3.2M | — | 2024-02-05 |
| Unique Diamond Investments Limited | 1.50% | 1.0M | — | 2024-07-22 |
| Foresite Capital Fund V, L.P. | 1.10% | 692.5K | — | 2024-02-05 |
Insider Transactions
Net 90d: −$1.26M · buys $0 / sells $1.26MRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-04-17 | James Mulay | Director | Option exercise | 15.6K | $36.63 | $571.4K |
| 2026-04-17 | James Mulay | Director | Sell (open market) | 15.6K | $73.01 | $1.14M |
| 2026-03-16 | James Mulay | Director | Option exercise | 654 | $3.72 | $2.4K |
| 2026-03-16 | James Mulay | Director | Sell (open market) | 654 | $63.50 | $41.5K |
| 2026-03-16 | James Mulay | Director | Option exercise | 1.3K | $12.59 | $16.5K |
| 2026-03-16 | James Mulay | Director | Sell (open market) | 1.3K | $63.50 | $83.2K |
| 2026-03-12 | Arthur Kuan | Chief Executive Officer | Option exercise | 64.6K | $1.72 | $111.1K |
| 2026-03-04 | Arthur Kuan | Chief Executive Officer | Option exercise | 102.9K | $1.72 | $176.9K |
1–8 of 8